Reception times

Martedì e giovedì ore 18,00-18,30 tramite piattaforma Teams

Curriculum

Dirigente di Ricerca presso l'Istituto Superiore di Sanità. Coordinamento di progetti di ricerca: • studio di cellule eritroleucemiche di Friend come modello differenziativo e di infezione cronica da retrovirus; • studio degli effetti biologici e molecolari degli interferoni rispetto alla loro attività antivirale, immunomodulatoria ed antiproliferativa; • analisi degli effetti adiuvanti degli interferoni e studio del loro utilizzo in terapie vaccinali; • studio della risposta delle cellule dendritiche dopo stimolazione con diversi patogeni, quali virus, Mycobacterium tuberculosis, Aspergillus fumigatus, Staphylococcus aureus; • analisi della regolazione dell’espressione genica indotta durante maturazione ed attivazione delle cellule dendritiche; • studio del ruolo delle cellule dendritiche plasmacitoidi nell’induzione e mantenimento di malattie infiammatorie croniche ed autoimmuni, quali artrite reumatoide e sclerosi multipla; • analisi della risposta alterata dei linfociti B e popolazioni monocitarie per identificare biomarcatori di malattie ed effcacia terapeutica nell’ambito dell sclerosi multipla: • studio delle alterazioni del processo autofagico indotte da patogeni per sovvertire la risposta immunitaria. Nell’ambito di queste attività ha preso parte a numerosi congressi e workshop nazionali ed internazionali, anche come relatrice di comunicazioni. I risultati ottenuti collaborando con altri gruppi di ricerca italiani ed esteri sono documentati dalle 127 pubblicazioni (H index 38 secondo Scopus). Attività istituzionale Valutazione in qualità di esperto Commissione per la valutazione dell’ammissibilità alla sperimentazione clinica di fase I diversi protocolli di immunoterapia adottiva e prodotti immunobiologici. Ha partecipato ad audizioni in cui si illustravano tali protocolli afferenti all’attività di Comma C, formulato pareri relativi a specialità farmaceutiche nell’ambito di procedure di mutuo riconoscimento e procedure centralizzate, valutato diversi progetti richiedenti autorizzazioni in deroga ai sensi del D.L.vo 116 del 27/1/1992 su richiesta del Servizio Qualità e Sicurezza della sperimentazione animale. Esperto presso la Farmacopea Europea per test relativo al rilevamento di possibili contaminanti pirogeni in preparazioni per uso clinico (Test per rilevare le endotossine batteriche). Pubblicazioni degli ultimi 5 anni • Giacomini E, Severa M, Rizzo F, Mechelli R, Annibali V, Ristori G, Riccieri V, Salvetti M, Coccia EM. IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients. Eur J Immunol. 2013;43:1963-72. • Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F, Battistini L. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9:e1003220. • Croia C, Serafini B, Bombardieri M, Kelly S, Humby F, Severa M, Rizzo F, Coccia EM, Migliorini P, Aloisi F, Pitzalis C. Epstein-Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis. Ann Rheum Dis. 2013 1;72:1559-68. • Severa M, Giacomini E, Gafa V, Anastasiadou E, Rizzo F, Corazzari M, Romagnoli A, Trivedi P, Fimia GM, Coccia EM. EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape. Eur J Immunol. 2013;43:147-58. • Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F and Battistini L. Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis. PlosPathogens 2013; 9:e1003220. • Giacomini E, Severa M, Rizzo F, Mechelli R, Annibali V, Ristori G, Riccieri V, Salvetti M, Coccia EM. IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients. Eur J Immunol. 2013; 43:1963-72 • Etna MP, Giacomini E, Severa M, Pardini M, Aguilo N, Martin C, Coccia EM. A human dendritic cell-based in vitro model to assess Mycobacterium tuberculosis SO2 vaccine immunogenicity. ALTEX. 2014 31:397-406. doi: http://dx.doi.org/10.14573/altex.1311041. • Etna MP, Giacomini E, Severa M, Coccia EM Pro- and anti-inflammatory cytokines in TB: a two-edged sword in TB pathogenesis. Semin Immunol. 2014;26:543-51. • Severa M, Giacomini E, Rizzo F, Salvetti M, Coccia EM. IFN-β and Multiple Sclerosis: cross-talking of immune cells and integration of immunoregulatory networks. Cytokine and Growth factor Reviews, 2015;26:229-39. • Annibali V, Buscarinu MC, Fornasiero A, Mechelli R, Romano S, Umeton R, Ricigliano VAG, Coccia EM, Salvetti M, Ristori G. IFN-β and Multiple Sclerosis: from etiology to therapy and back. Cytokine and Growth factor Reviews, 2015;26:221-28. • Battistini A, Coccia EM, Belardelli F. Interferon fundamentals: a tribute to the scientific vision of G B Rossi. Editorial. Cytokine Growth Factor Rev. 2015;26:95-7. • Giacomini E, Severa M, Cruciani M, Etna MP, Rizzo F, Pardini M, Scagnolari C, Garaci E and Coccia EM. Dual effect of thymosin alpha 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial Toll-like receptor agonists. Expert Opin Biol Ther, 2015;15 Suppl 1:S59-70. • Severa M, Rizzo F, Giacomini E, Annibali V, Gafa V, Romano S, Buscarinu MC, Fornasiero A, Salvetti M, Coccia EM. IFN- β therapy regulates TLR7-mediated response in plasmacytoid Dendritic Cells of Multiple Sclerosis patients influencing an anti-inflammatory status. J Interferon Cytokine Res, 2015;35(9):668-81. • Coccia EM, Battistini A. Early IFN type I response: Learning from microbial evasion strategies. Semin Immunol. 2015;27:85-101. • Etna MP, Giacomini E, Pardini M, Severa M, Bottai D, Cruciani M, Rizzo F, Calogero R, Brosch R, EM Coccia. Impact of Mycobacterium tuberculosis RD1-locus on human primary dendritic cell immune functions. Scientific Reports 2015;5:17078. • Martini H, Citro A, Martire C, D'Ettorre G, Labbadia G, Accapezzato D, Piconese S, De Marzio P, Cavallari EN, Calvo L, Rizzo F, Severa M, Coccia EM, Grazi GL, Di Filippo S, Sidney J, Vullo V, Sette A, Barnaba V. Apoptotic Epitope-Specific CD8+ T Cells and Interferon Signaling Intersect in Chronic Hepatitis C Virus Infection. J Infect Dis. 2016;213:674-83 • Monaco M, Pimentel de Araujo F, Cruciani M, Coccia EM°, Annalisa Pantosti ° (° shared seniorship). Worldwide epidemiology and antibiotic resistance. Current topics in microbiology 2016 Pacella I, Timperi E, Accapezzato D, Martire C, Labbadia G, Cavallari EN, D'Ettorre G, Calvo L, Rizzo F, Severa M, Coccia EM, Vullo V, Barnaba V, Piconese S. IFN-α promotes rapid human Treg contraction and late Th1-like Treg decrease. J Leukoc Biol. 2016;100:613-23. • Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1-222. • Rizzo F, Giacomini E, Mechelli R, Buscarinu MC, Salvetti M, Severa M, Coccia EM. Interferon-β therapy specifically reduces pathogenic memory B cells in Multiple Sclerosis patients by inducing a FAS-mediated apoptosis. Immunol Cell Biol. 2016;94:886-894. • Giacomini E, Rizzo F, Etna MP, Cruciani M, Mechelli R, Buscarinu MC, Pica F, D'Agostini C, Salvetti M, Coccia EM, Severa M. Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients. Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892. • Srinivasan S, Severa M, Rizzo F, Menon R, Brini E, Mechelli R, Martinelli V, Hertzog P, Salvetti M, Furlan R, Martino G, Comi G, Coccia E, Farina C. Transcriptional dysregulation of Interferome in experimental and human Multiple Sclerosis. Sci Rep. 2017;7:8981. doi: 10.1038/s41598-017-09286-y. • Cruciani M, Etna MP, Camilli R, Giacomini E, Percario ZA, Severa M, Sandini S, Rizzo F, Brandi V, Balsamo G, Polticelli F, Affabris E, Pantosti A, Bagnoli F, Coccia EM. Staphylococcus aureus Esx Factors Control Human Dendritic Cell Functions Conditioning Th1/Th17 Response. Front Cell Infect Microbiol. 2017;7:330. • Etna MP, Sinigaglia A, Grassi A, Giacomini E, Romagnoli A, Pardini M, Severa M, Cruciani M, Rizzo F, Anastasiadou E, Di Camillo B, Barzon L, Fimia GM, Manganelli R, Coccia EM. Mycobacterium tuberculosis-induced miR-155 subverts autophagy by targeting ATG3 in human dendritic cells. PLoS Pathog. 2018;14(1):e1006790. doi: 10.1371/journal.ppat.1006790. • Annibali V, Umeton R, Palermo A, Severa M, Etna MP, Giglio S, Romano S, Ferraldeschi M, Buscarinu MC, Vecchione A, Annese A, Policano C, Mechelli R, Pizzolato Umeton R, Fornasiero A, Angelini DF, Guerrera G, Battistini L, Coccia EM, Salvetti M, Ristori G Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. J Neuroimmunol. 2018;324:165-171. doi: 10.1016/j.jneuroim.2018.09.005. • Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C, Pepe G, Severa M, Rosenblatt J, Etna MP, Rieger S, Kempkes B, Coccia EM, Sui SJH, Chen CS, Uccini S, Avigan D, Faggioni A, Trivedi P, Slack FJ. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia. 2019;33(1):132-147. doi: 10.1038/s41375-018-0178-x. • Pacella I, Procaccini C, Focaccetti C, Miacci S, Timperi E, Faicchia D, Severa M, Rizzo F, Coccia EM, Bonacina F, Mitro N, Norata GD, Rossetti G, Ranzani V, Pagani M, Giorda E, Wei Y, Matarese G, Barnaba V, Piconese S. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc Natl Acad Sci U S A. 2018;115(28):E6546-E6555. doi: 10.1073/pnas.1720113115. • Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C, Pepe G, Severa M, Rosenblatt J, Etna MP, Rieger S, Kempkes B, Coccia E.M., Sui SJH, Chen CS, Uccini S, Avigan D, Faggioni A, Trivedi P, Slack FJ. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia. 2019; 33(1):132-147. • Severa M, Zhang J, Giacomini E, Rizzo F, Etna MP, Cruciani M, Garaci E, Chopp M, Coccia E.M. Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application. Mult Scler Relat Disord. 2019; 27:52-60. • Severa M, Rizzo F, Srinivasan S, Di Dario M, Giacomini E, Buscarinu MC, Cruciani M, Etna MP, Sandini S, Mechelli R, Farina A, Trivedi P, Hertzog PJ, Salvetti M, Farina C, Coccia E.M. A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in Multiple Sclerosis. J Autoimmun. 2019; doi: 10.1016/j.jaut.2019.04.006. • Severa M, Farina C, Salvetti M and Coccia E.M. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection? Front. Immunol. 2020 doi.org/10.3389/fimmu.2020.01459. • Etna MP, Giacomini E, Rizzo F, Severa M, Ricci D, Shaid S, Lambrigts D, Valentini S, Galli Stampino L, Alleri L, Gaggioli A, von Hunolstein C, Spreitzer I, Coccia E.M. Optimization of the monocyte-activation-test for evaluating pyrogenicity of tick-borne encephalitis virus vaccine. Altex 2020 doi.org/10.14573/altex.2002252. • Lorenzetti S, Aquilina G, Caloni F, Coccia E.M., Cozzini P, Cruciani G, Fouassier A, Gissi A, Goracci L, Heinonen T, Hubert P, Madia F, Nevelli F, Rainer A, Rovida C, Vitale A, De Angelis I. Non animal methodologies (NAMs): Research, testing, assessment and applications – Ecopa Symposium 2019. Altex 2020 doi.org/10.14573/altex.2003041. • Balducci S, Coccia E.M. Sedentariness and Physical Activity in Type 2 Diabetes mellitus during the COVID‐19 Pandemic; Diabetes Metab Res Rev. 2020: e3378. • Akkermans A, Chapsal JM, Coccia E.M., Depraetere H, Dierick JF, Duangkhae P, Goel S, Halder M, Hendriksen C, Levis R, Pinyosukhee K, Pullirsch D, Sanyal G, Shi L, Sitrin R, Smith D, Stickings P, Terao E, Uhlrich S, Viviani L, Webster J. Animal testing for vaccines. Implementing replacement, reduction and refinement: challenges and priorities. Biologicals. 2020 doi: 10.1016/j.biologicals.2020.07.010. • Ferrari M, Zevini A, Palermo E, Muscolini M, Alexandridi M, Etna MP, Coccia E.M., Fernandez-Sesma A, Coyne C, Zhang D, Marques ETA, Olagnier D, Hiscott J. Dengue virus targets Nrf2 for NS2B3-mediated degradation leading to enhanced oxidative stress and viral replication. J Virol. 2020 doi: 10.1128/JVI.01551-20. • Pacella I, Spinelli FR, Severa M, Timperi E, Tucci G, Zagaglioni M, Ceccarelli F, Rizzo F, Coccia E.M., Bogunovic D, Patel R, Martin-Fernandez M, Conti F, Barnaba V, Piconese S; ISG15 protects human Tregs from interferon alpha-induced contraction in a cell-intrinsic fashion; Clinical & Translational Immunol. 2020, doi: 10.1002/cti2.1221. • Signorazzi A, Etna MP, Coccia EM, Huckriede A; In vitro assessment of tick-borne encephalitis vaccine: Suitable human cell platforms and potential biomarkers. Altex. 2021, doi: 10.14573/altex.2010081. • Etna MP, Severa M, Licursi V, Pardini M, Cruciani M, Rizzo F, Giacomini E, Macchia G, Palumbo O, Stallone R, Carella M, Livingstone M, Negri R, Pellegrini S and Coccia EM; Genome-Wide Gene Expression Analysis of Mtb-Infected DC Highlights the Rapamycin-Driven Modulation of Regulatory Cytokines via the mTOR/GSK-3β Axis. Front. Immunol. 2021 doi: 10.3389/fimmu.2021.649475. • Klionsky DJ, et al, Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 2021; 17(1):1-382. doi: 10.1080/15548627.2020.1797280. • Etna MP, Signorazzi A, Ricci D, Severa M, Rizzo F, Giacomini E, Gaggioli A, Bekeredjian-Ding I, Huckriede A, and Coccia EM; Human plasmacytoid dendritic cells at the crossroad of type I interferon-regulated B cell differentiation and antiviral response to tick-borne encephalitis virus. Plos Pathogens 2021 Accepted.